EGFR amplification
|
NSCLC
|
EGFR amplification
|
NSCLC
|
gefitinib Sensitive: B - Late Trials
|
gefitinib Sensitive: B - Late Trials
|
EGFR amplification
|
SCCHN
|
EGFR amplification
|
SCCHN
|
afatinib Sensitive: B - Late Trials
|
afatinib Sensitive: B - Late Trials
|
EGFR amplification
|
NSCLC
|
EGFR amplification
|
NSCLC
|
erlotinib Sensitive: C2 – Inclusion Criteria
|
erlotinib Sensitive: C2 – Inclusion Criteria
|
EGFR amplification
|
GBM
|
EGFR amplification
|
GBM
|
ABT-414 Sensitive: C2 – Inclusion Criteria
|
ABT-414 Sensitive: C2 – Inclusion Criteria
|
EGFR amplification
|
GBM
|
EGFR amplification
|
GBM
|
lapatinib Sensitive: C2 – Inclusion Criteria
|
lapatinib Sensitive: C2 – Inclusion Criteria
|
EGFR amplification
|
GBM
|
EGFR amplification
|
GBM
|
erlotinib Resistant: C2 – Inclusion Criteria
|
erlotinib Resistant: C2 – Inclusion Criteria
|
EGFR amplification
|
Esophageal Squamous Cell Carcinoma
|
EGFR amplification
|
Esophageal Squamous Cell Carcinoma
|
afatinib Sensitive: C2 – Inclusion Criteria
|
afatinib Sensitive: C2 – Inclusion Criteria
|
EGFR amplification
|
Lung Cancer
|
EGFR amplification
|
Lung Cancer
|
gefitinib Resistant: C2 – Inclusion Criteria
|
gefitinib Resistant: C2 – Inclusion Criteria
|
EGFR amplification
|
GBM
|
EGFR amplification
|
GBM
|
KD019 Sensitive: C2 – Inclusion Criteria
|
KD019 Sensitive: C2 – Inclusion Criteria
|
EGFR amplification
|
Glioma
|
EGFR amplification
|
Glioma
|
ABT-414 Sensitive: C2 – Inclusion Criteria
|
ABT-414 Sensitive: C2 – Inclusion Criteria
|
EGFR amplification
|
SCCHN
|
EGFR amplification
|
SCCHN
|
Immunotherapy Resistant: C3 – Early Trials
|
Immunotherapy Resistant: C3 – Early Trials
|
EGFR amplification
|
Gastric Cancer
|
EGFR amplification
|
Gastric Cancer
|
cetuximab Sensitive: C3 – Early Trials
|
cetuximab Sensitive: C3 – Early Trials
|
EGFR amplification
|
Melanoma
|
EGFR amplification
|
Melanoma
|
Immunotherapy Resistant: C3 – Early Trials
|
Immunotherapy Resistant: C3 – Early Trials
|
EGFR amplification
|
Mucosal Melanoma
|
EGFR amplification
|
Mucosal Melanoma
|
ipilimumab Resistant: C3 – Early Trials
|
ipilimumab Resistant: C3 – Early Trials
|
EGFR amplification
|
Mucosal Melanoma
|
EGFR amplification
|
Mucosal Melanoma
|
nivolumab Resistant: C3 – Early Trials
|
nivolumab Resistant: C3 – Early Trials
|
EGFR amplification
|
Mucosal Melanoma
|
EGFR amplification
|
Mucosal Melanoma
|
nivolumab + ipilimumab Resistant: C3 – Early Trials
|
nivolumab + ipilimumab Resistant: C3 – Early Trials
|
EGFR amplification
|
Mucosal Melanoma
|
EGFR amplification
|
Mucosal Melanoma
|
pembrolizumab Resistant: C3 – Early Trials
|
pembrolizumab Resistant: C3 – Early Trials
|
EGFR amplification
|
CRC
|
EGFR amplification
|
CRC
|
cetuximab Resistant: C3 – Early Trials
|
cetuximab Resistant: C3 – Early Trials
|
EGFR amplification
|
CRC
|
EGFR amplification
|
CRC
|
panitumumab Sensitive: C3 – Early Trials
|
panitumumab Sensitive: C3 – Early Trials
|
EGFR amplification
|
NSCLC
|
EGFR amplification
|
NSCLC
|
osimertinib Resistant: C3 – Early Trials
|
osimertinib Resistant: C3 – Early Trials
|
EGFR amplification
|
Solid Tumor
|
EGFR amplification
|
Solid Tumor
|
ABSK091 Sensitive: C3 – Early Trials
|
ABSK091 Sensitive: C3 – Early Trials
|
EGFR amplification
|
Lung Cancer
|
EGFR amplification
|
Lung Cancer
|
icotinib Resistant: C3 – Early Trials
|
icotinib Resistant: C3 – Early Trials
|
EGFR amplification
|
NSCLC
|
EGFR amplification
|
NSCLC
|
bevacizumab + erlotinib Sensitive: C3 – Early Trials
|
bevacizumab + erlotinib Sensitive: C3 – Early Trials
|
EGFR amplification
|
NSCLC
|
EGFR amplification
|
NSCLC
|
bevacizumab + gefitinib Sensitive: C3 – Early Trials
|
bevacizumab + gefitinib Sensitive: C3 – Early Trials
|
EGFR amplification
|
SCCHN
|
EGFR amplification
|
SCCHN
|
pembrolizumab + afatinib Sensitive: C3 – Early Trials
|
pembrolizumab + afatinib Sensitive: C3 – Early Trials
|
EGFR amplification
|
Gastric Cancer
|
EGFR amplification
|
Gastric Cancer
|
EGFR inhibitor Sensitive: C3 – Early Trials
|
EGFR inhibitor Sensitive: C3 – Early Trials
|
EGFR amplification
|
Esophageal Cancer
|
EGFR amplification
|
Esophageal Cancer
|
EGFR inhibitor Sensitive: C3 – Early Trials
|
EGFR inhibitor Sensitive: C3 – Early Trials
|
EGFR amplification
|
NSCLC
|
EGFR amplification
|
NSCLC
|
KN046 Sensitive: C3 – Early Trials
|
KN046 Sensitive: C3 – Early Trials
|
EGFR amplification
|
Esophageal Squamous Cell Carcinoma
|
EGFR amplification
|
Esophageal Squamous Cell Carcinoma
|
Z650 Sensitive: C3 – Early Trials
|
Z650 Sensitive: C3 – Early Trials
|
EGFR amplification
|
LUAD
|
EGFR amplification
|
LUAD
|
afatinib Sensitive: C4 – Case Studies
|
afatinib Sensitive: C4 – Case Studies
|
EGFR amplification
|
Triple Negative Breast Cancer
|
EGFR amplification
|
Triple Negative Breast Cancer
|
cetuximab Sensitive: C4 – Case Studies
|
cetuximab Sensitive: C4 – Case Studies
|
EGFR amplification
|
GBM
|
EGFR amplification
|
GBM
|
verteporfin Sensitive: D – Preclinical
|
verteporfin Sensitive: D – Preclinical
|
EGFR amplification
|
Glioma
|
EGFR amplification
|
Glioma
|
talazoparib Sensitive: D – Preclinical
|
talazoparib Sensitive: D – Preclinical
|
EGFR amplification
|
Oral Cancer
|
EGFR amplification
|
Oral Cancer
|
afatinib Sensitive: D – Preclinical
|
afatinib Sensitive: D – Preclinical
|
EGFR amplification
|
Oral Cancer
|
EGFR amplification
|
Oral Cancer
|
AZD0530 Sensitive: D – Preclinical
|
AZD0530 Sensitive: D – Preclinical
|
EGFR amplification
|
Oral Cancer
|
EGFR amplification
|
Oral Cancer
|
lapatinib Sensitive: D – Preclinical
|
lapatinib Sensitive: D – Preclinical
|
EGFR amplification
|
Oral Cancer
|
EGFR amplification
|
Oral Cancer
|
gefitinib Sensitive: D – Preclinical
|
gefitinib Sensitive: D – Preclinical
|
EGFR amplification
|
Oral Cancer
|
EGFR amplification
|
Oral Cancer
|
erlotinib Sensitive: D – Preclinical
|
erlotinib Sensitive: D – Preclinical
|
EGFR amplification
|
Oral Cancer
|
EGFR amplification
|
Oral Cancer
|
cetuximab Sensitive: D – Preclinical
|
cetuximab Sensitive: D – Preclinical
|